Table 3.
ctDNA gene mutations of 16 Fulvestrant second- or higher-line users
| Covariate | Overall (N = 16) | PFS subgroups | ||
|---|---|---|---|---|
| PFS < 6 months (n = 10) | PFS > 6 months (n = 6) | p-value* | ||
| PIK3CA | 10 (62.50%) | 7 (70.00%) | 3 (50.00%) | 0.61 |
| TP53 | 4 (25.00%) | 3 (30.00%) | 1 (16.67%) | 1.00 |
| ESR1 | 2 (12.50%) | 2 (20.00%) | 0 (0%) | 0.50 |
| ERBB2 | 4 (25.00%) | 4 (40.00%) | 0 (0%) | 0.23 |
| ESR1/ERBB2 | 6 (37.50%) | 6 (60.00%) | 0 (0%) | 0.03 |
| TP53/ESR1/ERBB2 | 8 (50.00%) | 7 (70.00%) | 1 (16.67%) | 0.11 |
According to their PFS lengths, these patients were divided into two subgroups: PFS < 6 months and PFS > 6 months
* p-values were calculated by using Fisher’s exact tests (n < 5) for categorical variables comparison between PFS < 6 months group and PFS > 6 months group